<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02862912</url>
  </required_header>
  <id_info>
    <org_study_id>AAAQ0916</org_study_id>
    <nct_id>NCT02862912</nct_id>
  </id_info>
  <brief_title>Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)</brief_title>
  <official_title>Chloroprocaine Versus Bupivacaine Spinal Anesthesia for Cervical Cerclage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine whether or not spinal anesthesia with the local anesthetic drug,&#xD;
      chloroprocaine, wears off faster than the local anesthetic drug, bupivacaine, and results in&#xD;
      faster discharge from the post-anesthesia care unit after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, randomized, double blind clinical trial. Subjects will be ASA I&#xD;
      and II women ≥18 yrs old with a singleton pregnancy in the 1st or 2nd trimester of pregnancy&#xD;
      undergoing cervical cerclage with spinal anesthesia. Patients will be randomly allocated to&#xD;
      the chloroprocaine (CP) or bupivacaine group (BUP). Patients will receive spinal anesthesia&#xD;
      with either chloroprocaine 50 mg with fentanyl 15 mcg or bupivacaine 9 mg with fentanyl 15&#xD;
      mcg.&#xD;
&#xD;
      Bupivacaine is the most common local anesthetic used for cervical cerclage with spinal&#xD;
      anesthesia. Bupivacaine is safe and has been preferred over other medications such as&#xD;
      lidocaine, because it is associated with a low incidence of a complication from spinal&#xD;
      anesthesia known as &quot;transient neurologic symptoms&quot; - a condition where pain and cramping in&#xD;
      the buttocks and lower extremities can be experienced for several days. Bupivacaine is a&#xD;
      long-acting local anesthetic agent and therefore has the disadvantage of a prolonged&#xD;
      anesthetic recovery that may last a few hours.&#xD;
&#xD;
      Chloroprocaine is a local anesthetic with a fast onset and short duration that may be used&#xD;
      for spinal anesthesia for ambulatory procedures. Chloroprocaine is currently used at the&#xD;
      research institution for spinal anesthesia for ambulatory surgical patients, especially for&#xD;
      lower extremity orthopedic procedures such as knee arthroscopy, as well as for pregnant&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2016</start_date>
  <completion_date type="Actual">January 31, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of Motor Block</measure>
    <time_frame>3 hours</time_frame>
    <description>The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale:&#xD;
Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulate</measure>
    <time_frame>5 hours</time_frame>
    <description>Time from spinal anesthesia placement to ability to ambulate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Void</measure>
    <time_frame>5 hours</time_frame>
    <description>Time from spinal anesthesia injection to ability to void spontaneously.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Adverse Reaction to Spinal Anesthetic</condition>
  <condition>Maternal Care for Cervical Incompetence</condition>
  <arm_group>
    <arm_group_label>Chloroprocaine (CP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine (BUP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroprocaine</intervention_name>
    <description>Administered as a single injection or continuously through an indwelling catheter - 50 mg</description>
    <arm_group_label>Chloroprocaine (CP)</arm_group_label>
    <other_name>Nesacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)</description>
    <arm_group_label>Bupivacaine (BUP)</arm_group_label>
    <other_name>Bupivacaine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
    <arm_group_label>Bupivacaine (BUP)</arm_group_label>
    <arm_group_label>Chloroprocaine (CP)</arm_group_label>
    <other_name>Sublimaze</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
    <arm_group_label>Bupivacaine (BUP)</arm_group_label>
    <other_name>Salt water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I and II women&#xD;
&#xD;
          -  18-45 yrs old&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Cervical cerclage 1st or 2nd trimester of pregnancy undergoing with spinal anesthesia&#xD;
&#xD;
          -  Height 150 - 180 cm&#xD;
&#xD;
          -  BMI ≤ 40 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to neuraxial anesthesia (history of neurologic disease (e.g.,&#xD;
             multiple sclerosis, spinal stenosis, central or peripheral neuropathy)&#xD;
&#xD;
          -  Pre-existing/chronic back pain&#xD;
&#xD;
          -  Ester local anesthetic allergy, PABA allergy&#xD;
&#xD;
          -  History of atypical cholinesterase (CP is metabolized by cholinesterase)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Smiley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Camponovo C, Wulf H, Ghisi D, Fanelli A, Riva T, Cristina D, Vassiliou T, Leschka K, Fanelli G. Intrathecal 1% 2-chloroprocaine vs. 0.5% bupivacaine in ambulatory surgery: a prospective, observer-blinded, randomised, controlled trial. Acta Anaesthesiol Scand. 2014 May;58(5):560-6. doi: 10.1111/aas.12291. Epub 2014 Mar 6.</citation>
    <PMID>24601887</PMID>
  </reference>
  <reference>
    <citation>Hejtmanek MR, Pollock JE. Chloroprocaine for spinal anesthesia: a retrospective analysis. Acta Anaesthesiol Scand. 2011 Mar;55(3):267-72. doi: 10.1111/j.1399-6576.2010.02371.x.</citation>
    <PMID>21288208</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <results_first_submitted>May 7, 2020</results_first_submitted>
  <results_first_submitted_qc>May 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 26, 2020</results_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Richard M. Smiley</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Chloroprocaine</keyword>
  <keyword>cervical cerclage</keyword>
  <keyword>spinal anesthesia</keyword>
  <keyword>Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Incompetence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Chloroprocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A research report will be written and submitted to a peer-reviewed journal</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Submission will be made by December, 2020. Publication availability is to be determined by the peer review process. Once published, the data should be available indefinitely.</ipd_time_frame>
    <ipd_access_criteria>To be determined.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02862912/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT02862912/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chloroprocaine (CP)</title>
          <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)&#xD;
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine (BUP)</title>
          <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml&#xD;
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups&#xD;
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Women with an indication for cervical cerclage with spinal anesthesia</population>
      <group_list>
        <group group_id="B1">
          <title>Chloroprocaine (CP)</title>
          <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)&#xD;
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine (BUP)</title>
          <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml&#xD;
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups&#xD;
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="4"/>
                    <measurement group_id="B2" value="34" spread="6"/>
                    <measurement group_id="B3" value="33" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Resolution of Motor Block</title>
        <description>The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale:&#xD;
Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)</description>
        <time_frame>3 hours</time_frame>
        <population>One protocol violation in the chloroprocaine group led to 22 subjects being analyzed. One block failure in the bupivacaine group led to 19 subjects being analyzed. During analysis it was noted that the motor and sensory block resolution data was missing for 2 subjects in the bupivacaine group so only partial data was available. As a result, 17 participants were analyzed in the bupivacaine group.</population>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine (CP)</title>
            <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)&#xD;
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine (BUP)</title>
            <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml&#xD;
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups&#xD;
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Resolution of Motor Block</title>
          <description>The mean difference between groups in time between the end of spinal injection (t IT) to time for no motor block (t motor), i.e. tIT - T motor. Motor block will be assessed using the Bromage scale:&#xD;
Bromage Scale I = free movement of the legs and feet = no block II = able to flex knees, with free movement of feet = partial (33%) block III = unable to flex knees, but with free movement of the feet = almost complete (66%) block IV = unable to move legs or feet = complete block (100%)</description>
          <population>One protocol violation in the chloroprocaine group led to 22 subjects being analyzed. One block failure in the bupivacaine group led to 19 subjects being analyzed. During analysis it was noted that the motor and sensory block resolution data was missing for 2 subjects in the bupivacaine group so only partial data was available. As a result, 17 participants were analyzed in the bupivacaine group.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" lower_limit="88" upper_limit="148"/>
                    <measurement group_id="O2" value="112" lower_limit="97" upper_limit="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ambulate</title>
        <description>Time from spinal anesthesia placement to ability to ambulate.</description>
        <time_frame>5 hours</time_frame>
        <population>One protocol violation in the chloroprocaine group led to 22 subjects being analyzed. One block failure in the bupivacaine group led to 19 subjects being analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Chloroprocaine (CP)</title>
            <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)&#xD;
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine (BUP)</title>
            <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml&#xD;
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups&#xD;
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulate</title>
          <description>Time from spinal anesthesia placement to ability to ambulate.</description>
          <population>One protocol violation in the chloroprocaine group led to 22 subjects being analyzed. One block failure in the bupivacaine group led to 19 subjects being analyzed.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158" lower_limit="137" upper_limit="188"/>
                    <measurement group_id="O2" value="229" lower_limit="186" upper_limit="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Void</title>
        <description>Time from spinal anesthesia injection to ability to void spontaneously.</description>
        <time_frame>5 hours</time_frame>
        <population>In practice, time to void coincided with time to ambulate (to use toilet) and the data is therefore identical to time to ambulate (also time to meet discharge criteria in practice). One protocol violation in the chloroprocaine group led to 22 subjects being analyzed. One block failure in the bupivacaine group led to 19 subjects being analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Bupivacaine (BUP)</title>
            <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml&#xD;
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups&#xD;
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
          </group>
          <group group_id="O2">
            <title>Chloroprocaine (CP)</title>
            <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)&#xD;
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Void</title>
          <description>Time from spinal anesthesia injection to ability to void spontaneously.</description>
          <population>In practice, time to void coincided with time to ambulate (to use toilet) and the data is therefore identical to time to ambulate (also time to meet discharge criteria in practice). One protocol violation in the chloroprocaine group led to 22 subjects being analyzed. One block failure in the bupivacaine group led to 19 subjects being analyzed.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" lower_limit="186" upper_limit="332"/>
                    <measurement group_id="O2" value="158" lower_limit="137" upper_limit="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to postoperative day 1</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chloroprocaine (CP)</title>
          <description>Patients in CP group will receive 3% 2-chloroprocaine 50 mg (1.67 ml) and fentanyl 15 mcg (0.3 ml)&#xD;
Chloroprocaine: Administered as a single injection or continuously through an indwelling catheter - 50 mg&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine (BUP)</title>
          <description>Patients in BUP group will receive hyperbaric 0.75% bupivacaine 9 mg (1.4 ml), with fentanyl 15 mcg (0.3 ml), with saline (0.3 ml) to bring the volume to ~ 2 ml&#xD;
Bupivacaine: A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)&#xD;
Fentanyl: 15 mcg Fentanyl will be included int he spinal anesthetic in both groups&#xD;
Saline: Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Despite low dropout risk, we proposed to enroll an additional 4 subjects/group above calculated sample size. The significantly shorter discharge times among some subjects became increasingly apparent. It became untenable to claim clinical equipoise. After the originally calculated sample size was achieved, we decided to stop enrolling new cases, accounting for uneven group numbers. A Shapiro-Wilk test indicated block resolution and discharge time data was non-normal (medians [IQR] reported).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Allison Lee</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-6494</phone>
      <email>al3196@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

